Modality
Vaccine
MOA
JAK1/2i
Target
AuroraA
Pathway
RAS/MAPK
MigraineObesityCervical Ca
Development Pipeline
Preclinical
~Oct 2013
→ ~Jan 2015
Phase 1
~Apr 2015
→ ~Jul 2016
Phase 2
~Oct 2016
→ ~Jan 2018
Phase 3
Apr 2018
→ Nov 2025
Phase 3Current
NCT05510816
1,298 pts·Migraine
2018-04→2025-04·Active
NCT05240131
529 pts·Cervical Ca
2019-03→2025-11·Recruiting
1,827 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-04-0212mo agoPh3 Readout· Migraine
2025-11-085mo agoPh3 Readout· Cervical Ca
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
P3
Active
P3
Recruit…
Catalysts
Ph3 Readout
2025-04-02 · 12mo ago
Migraine
Ph3 Readout
2025-11-08 · 5mo ago
Cervical Ca
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05510816 | Phase 3 | Migraine | Active | 1298 | 6MWD |
| NCT05240131 | Phase 3 | Cervical Ca | Recruiting | 529 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Fixanesiran | AbbVie | Preclinical | RET | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| ARG-6988 | Argenx | Preclinical | AuroraA | |
| Sovarelsin | BioMarin | Phase 2 | CFTR | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Niramavacamten | Hansoh Pharma | Phase 2 | SGLT2 |